News

Amgen (AMGN) reported $10.05 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 9.5%. EPS of $6.29 for the same period compares to $6.02 a year ago.

The reported revenue represents a surprise of +6.52% over the Zacks Consensus Estimate of $9.44 billion. With the consensus EPS estimate being $5.60, the EPS surprise was +12.32%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Amgen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Product Sales- Vectibix- U.S.: $167 million versus $153.22 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +16% change.
• Product Sales- Neulasta- ROW: $15 million versus the five-analyst average estimate of $16.62 million. The reported number represents a year-over-year change of -21.1%.
• Product Sales- Prolia- U.S.: $478 million compared to the $442.94 million average estimate based on five analysts. The reported number represents a change of -35.8% year over year.
• Product Sales- IMDELLTRA/IMDYLLTRA- U.S.: $233 million versus $209.32 million estimated by five analysts on average.
• Product Sales- BLINCYTO- Total: $472 million compared to the $457.17 million average estimate based on six analysts. The reported number represents a change of +22.9% year over year.
• Product Sales- KYPROLIS- Total: $314 million compared to the $359.8 million average estimate based on six analysts. The reported number represents a change of -16.9% year over year.
• Product Sales- Repatha- Total: $953 million versus $907.08 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +36.9% change.
• Product Sales- XGEVA- Total: $352 million compared to the $355.96 million average estimate based on six analysts. The reported number represents a change of -33.8% year over year.
• Product Sales- Prolia- Total: $759 million versus $728.36 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a -32.4% change.
• Product Sales- Nplate- Total: $430 million versus the six-analyst average estimate of $389.27 million. The reported number represents a year-over-year change of +16.5%.
• Product Sales- Vectibix- Total: $338 million versus the six-analyst average estimate of $317.2 million. The reported number represents a year-over-year change of +10.8%.
• Product Sales- Enbrel- Total: $580 million versus $466.48 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a -4% change.

Shares of Amgen have returned +3.4% over the past month versus the Zacks S&P 500 composite's +1.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.